Overview: 3-Hydroxyglutaric Acid TestIntroduction: The 3-Hydroxyglutaric Acid Test tests for Glutaric Aciduria Type I, a metabolic disorder that can cause brain damage, movement problems, or seizures in children if untreated, helping ensure early treatment to prevent complications. With a prevalence of 1 in 30,000 to 1 in 100,000, particularly in Amish communities or Scandinavian populations, this condition results from GCDH gene mutations, requiring early detection to mitigate striatal injury and dystonia. Following 2023 ACMG guidelines, it uses gas chromatography-mass spectrometry (GC-MS) for high specificity, supporting neurological screening. This test is essential for diagnosis, treatment planning, and improving outcomes in biochemistry, especially in pediatric care where delayed diagnosis can lead to irreversible neurological deficits.
Other Names: 3-HGA Assay, Glutarate Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic precision.
Historical Milestone: Testing began in the 1990s with metabolic research by Stephen Goodman, who linked glutaric aciduria to neurological outcomes through organic acid analysis. GC-MS advancements in the 2000s by mass spectrometry experts like Ronald Wanders enhanced detection of 3-hydroxyglutaric acid, surpassing earlier gas-liquid chromatography methods that lacked resolution for low-abundance metabolites.
Purpose: Measures 3-hydroxyglutaric acid levels to diagnose Glutaric Aciduria Type I, guides dietary therapy with lysine restriction and carnitine supplementation, and evaluates children with movement issues, seizures, or developmental delays, aiming to prevent acute encephalopathic crises that can result in coma or death.
Test Parameters: 3-HGA levels
Pretest Condition: No special preparation required to reflect natural metabolite levels. Collect urine or plasma. Report history of neurological symptoms, developmental delays, or recent infections that might trigger crises.
Specimen: Urine (sterile container, 5-20 mL), Plasma (NaHep, 2-4 mL); 10 mL urine in sterile container. Transport in a biohazard container to maintain sample integrity.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document movement problems, seizures, or developmental delays. Include dietary history, recent illnesses, or family history of metabolic disorders, noting any protein-rich diet exposure that could exacerbate symptoms.
Consent: Written consent required, detailing the test's purpose, Glutaric Aciduria risks (e.g., encephalopathy, macrocephaly), and potential risks of sample collection, with emphasis on genetic counseling and long-term neurological follow-up to monitor progression.
Procedural Considerations: Uses GC-MS to measure 3-HGA levels, requiring laboratories with Agilent 7890A GC-MS systems and trained technicians to handle volatile organic acids. Results are available in 2-3 days, supporting pediatric care. Performed in labs with strict sample preservation protocols, including immediate refrigeration if analysis is delayed, to prevent metabolite loss.
Factors Affecting Result Accuracy: Improper sample collection, contamination with bacteria, or exposure to heat can affect results. Dietary protein intake, dehydration, or medications may influence levels, necessitating controlled sampling and clinical correlation to avoid misinterpretation.
Clinical Significance: Elevated 3-HGA confirms Glutaric Aciduria Type I, guiding lysine-restricted diets and emergency protocols during illness with intravenous glucose. A child with early treatment might avoid dystonia or basal ganglia injury, while untreated cases can lead to permanent disability or sudden death. Normal levels may require brain MRI or genetic testing (e.g., GCDH sequencing) to rule out asymptomatic carriers or alternative diagnoses.
Specialist Consultation: Consult a neurologist or metabolic specialist for result interpretation and management, particularly for infants or those with macrocephaly, where multidisciplinary care involving dietitians and neurologists is critical to prevent crises.
Additional Supporting Tests: Brain MRI to assess striatal lesions, GCDH gene analysis, or urine organic acids to confirm Glutaric Aciduria Type I diagnosis and guide therapy, addressing potential dietary triggers and long-term neurological risks.
Test Limitations: Non-specific for disease severity or acute vs. chronic phases; clinical correlation with imaging and history is needed. Sample quality affects sensitivity, and false negatives may occur in early infancy, requiring repeat testing during symptomatic periods.
References: ACMG Guidelines, 2023; Journal of Inherited Metabolic Disease, Kolker S, 2022.
